Related references
Note: Only part of the references are listed.The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
Dietmar W. Siemann
CANCER TREATMENT REVIEWS (2011)
CONCURRENT CISPLATIN AND RADIATION VERSUS CETUXIMAB AND RADIATION FOR LOCALLY ADVANCED HEAD-AND-NECK CANCER
Lawrence Koutcher et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Disrupting Established Tumor Blood Vessels An Emerging Therapeutic Strategy for Cancer
Mark J. McKeage et al.
CANCER (2010)
Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer
Shanthi Marur et al.
CURRENT OPINION IN ONCOLOGY (2010)
Emerging drugs to treat squamous cell carcinomas of the head and neck
Christopher Fung et al.
EXPERT OPINION ON EMERGING DRUGS (2010)
AVE8062: a new combretastatin derivative vascular disrupting agent
Angelo Delmonte et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Pharmacotherapy of head and neck squamous cell carcinoma
Quintin Pan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies
Chryso Kanthou et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2009)
Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
Oleksandr Ekshyyan et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth
Katsuyoshi Hori et al.
CANCER SCIENCE (2008)
Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography
Sonia Lavisse et al.
INVESTIGATIVE RADIOLOGY (2008)
How do microtubule-targeted drugs work? An overview
Mary Ann Jordan et al.
CURRENT CANCER DRUG TARGETS (2007)
Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18f-fdg uptake as determined by pet imaging
Andrean L. Simons et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
The epidermal growth factor receptor: A role in repair of radiation-induced DNA damage
David J. Chen et al.
CLINICAL CANCER RESEARCH (2007)
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma
Tae Jin Kim et al.
CANCER RESEARCH (2007)
Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo
Felix Y. Feng et al.
CLINICAL CANCER RESEARCH (2007)
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies
Michael R. Horsman et al.
CANCER RESEARCH (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase
K Dittmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity
K Dittmann et al.
RADIOTHERAPY AND ONCOLOGY (2005)
Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation:: a study on C225 in FaDu hSCC
M Krause et al.
RADIOTHERAPY AND ONCOLOGY (2005)
Vascular targeting agents as cancer therapeutics
PE Thorpe
CLINICAL CANCER RESEARCH (2004)
Mismatch repair gene expression and genetic instability in testicular germ cell tumor
A Velasco et al.
CANCER BIOLOGY & THERAPY (2004)
Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis
K Hori et al.
BRITISH JOURNAL OF CANCER (2003)
Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo
Y Morinaga et al.
CANCER SCIENCE (2003)
The development of combretastatin A4 phosphate as a vascular targeting agent
DJ Chaplin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
K Hori et al.
BRITISH JOURNAL OF CANCER (2002)
Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation
PM Harari et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Share Paper
